相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer
Thomas A. Waldmann et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model
Hideki Furuya et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy
Karin M. Knudson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Development of a recombinant human IL-15•sIL-15Rα/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model
Meiqi Zhao et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion
Kevin C. Conlon et al.
CLINICAL CANCER RESEARCH (2019)
First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia
Sarah Cooley et al.
BLOOD ADVANCES (2019)
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
Rizwan Romee et al.
BLOOD (2018)
Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques
Cristina Bergamaschi et al.
CYTOKINE (2018)
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
John M. Wrangle et al.
LANCET ONCOLOGY (2018)
Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade
Stacy J. Kowalsky et al.
MOLECULAR THERAPY (2018)
IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages
Meili Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors
Kim Margolin et al.
CLINICAL CANCER RESEARCH (2018)
A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors
Jeffrey S. Miller et al.
CLINICAL CANCER RESEARCH (2018)
Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect
Martin Felices et al.
JCI INSIGHT (2018)
IL-15 sustains IL-7R-independent ILC2 and ILC3 development
Michelle L. Robinette et al.
NATURE COMMUNICATIONS (2017)
IL15 Infusion of Cancer Patients Expands the Subpopulation of Cytotoxic CD56bright NK Cells and Increases NK-Cell Cytokine Release Capabilities
Sigrid Dubois et al.
CANCER IMMUNOLOGY RESEARCH (2017)
HiJAKing Innate Lymphoid Cells?
Giuseppe Sciume et al.
FRONTIERS IN IMMUNOLOGY (2017)
The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas
Maximillian Rosario et al.
CLINICAL CANCER RESEARCH (2016)
Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement
Rony Dahan et al.
CANCER CELL (2016)
A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses
Bai Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists
Melanie Desbois et al.
JOURNAL OF IMMUNOLOGY (2016)
Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker
Joerg U. Schmohl et al.
MOLECULAR THERAPY (2016)
CIS is a potent checkpoint in NK cell-mediated tumor immunity
Rebecca B. Delconte et al.
NATURE IMMUNOLOGY (2016)
TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection
Glen M. Chew et al.
PLOS PATHOGENS (2016)
CIS is a negative regulator of IL-15-mediated signals in NK cells
Cristina Bottino et al.
TRANSLATIONAL CANCER RESEARCH (2016)
Out-of-Sequence Signal 3 Paralyzes Primary CD4+ T-Cell-Dependent Immunity
Gail D. Sckisel et al.
IMMUNITY (2015)
Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
Kevin C. Conlon et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Combination therapy of an IL-15 superagonist complex, ALT-803, and a tumor targeting monoclonal antibody promotes direct antitumor activity and protective vaccinal effect in a syngenic mouse melanoma model
Xiaoyue Chen et al.
Journal for ImmunoTherapy of Cancer (2015)
Molecular Pathways: Interleukin-15 Signaling in Health and in Cancer
Anjali Mishra et al.
CLINICAL CANCER RESEARCH (2014)
T-bet Orchestrates CD8αα IEL Differentiation
Brandon Kwong et al.
IMMUNITY (2014)
The Transcription Factor T-bet Is Induced by IL-15 and Thymic Agonist Selection and Controls CD8αα+ Intraepithelial Lymphocyte Development
Christoph S. N. Klose et al.
IMMUNITY (2014)
The unconventional expression of IL-15 and its role in NK cell homeostasis
Nicholas D. Huntington
IMMUNOLOGY AND CELL BIOLOGY (2014)
IL-2: The First Effective Immunotherapy for Human Cancer
Steven A. Rosenberg
JOURNAL OF IMMUNOLOGY (2014)
Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse
Marie Vincent et al.
MABS (2014)
Intraepithelial Type 1 Innate Lymphoid Cells Are a Unique Subset of IL-12-and IL-15-Responsive IFN-γ-Producing Cells
Anja Fuchs et al.
IMMUNITY (2013)
Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency
Marie Vincent et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Characterization and Favorable in Vivo Properties of Heterodimeric Soluble IL-15•IL-15Rα Cytokine Compared to IL-15 Monomer
Elena Chertova et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin
Laura K. Mackay et al.
NATURE IMMUNOLOGY (2013)
IL-15 cis Presentation Is Required for Optimal NK Cell Activation in Lipopolysaccharide-Mediated Inflammatory Conditions
Ivan Zanoni et al.
CELL REPORTS (2013)
Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum
Cristina Bergamaschi et al.
BLOOD (2012)
Regulating the immune system via IL-15 transpresentation
Eliseo F. Castillo et al.
CYTOKINE (2012)
Augmented IL-15Rα Expression by CD40 Activation Is Critical in Synergistic CD8 T Cell-Mediated Antitumor Activity of Anti-CD40 Antibody with IL-15 in TRAMP-C2 Tumors in Mice
Meili Zhang et al.
JOURNAL OF IMMUNOLOGY (2012)
Antigen-Independent Induction of Tim-3 Expression on Human T Cells by the Common γ-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Is Associated with Proliferation and Is Dependent on the Phosphoinositide 3-Kinase Pathway
Shariq Mujib et al.
JOURNAL OF IMMUNOLOGY (2012)
Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model
Ping Yu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Adoptive immunotherapy for cancer: harnessing the T cell response
Nicholas P. Restifo et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques
Thomas A. Waldmann et al.
BLOOD (2011)
IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood
Michael C. Sneller et al.
BLOOD (2011)
IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR
M. P. Roberti et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression
Esther Moga et al.
EXPERIMENTAL HEMATOLOGY (2011)
Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies
Fubin Li et al.
SCIENCE (2011)
Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model
Ping Yu et al.
CLINICAL CANCER RESEARCH (2010)
The power and the promise of restimulation-induced cell death in human immune diseases
Andrew L. Snow et al.
IMMUNOLOGICAL REVIEWS (2010)
Homeostatic proliferation and survival of naive and memory T cells
Onur Boyman et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
IL-15 trans-presentation promotes human NK cell development and differentiation in vivo
Nicholas D. Huntington et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Novel Human Interleukin-15 Agonists
Xiaoyun Zhu et al.
JOURNAL OF IMMUNOLOGY (2009)
High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor α fusion protein, in metastatic melanoma and colorectal cancer
Anne Bessard et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer
Meili Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
CD8+CD122+ regulatory T cells recognize activated T cells via conventional MHC class I-αβTCR interaction and become IL-10-producing active regulatory cells
Muhaimin Rifa'i et al.
INTERNATIONAL IMMUNOLOGY (2008)
Intracellular interaction of interleukin-15 with its receptor α during production leads to mutual stabilization and increased bioactivity
Cristina Bergamaschi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Dendritic cells prime natural killer cells by trans-presenting interleukin 15
Mathias Lucas et al.
IMMUNITY (2007)
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
Thomas A. Waldmann
NATURE REVIEWS IMMUNOLOGY (2006)
Human natural killer cell development and biology
Sherif S. Farag et al.
BLOOD REVIEWS (2006)
Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors
RM Teague et al.
NATURE MEDICINE (2006)
Soluble interleukin-15 receptor α (IL-15Rα)-sushi as a selective and potent agonist of IL-15 action through IL-15Rβ/γ -: Hyperagonist IL-15•IL-15Rα fusion proteins
E Mortier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance
H Kobayashi et al.
BLOOD (2005)
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells
CA Klebanoff et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Cytokine control of memory T-cell development and survival
KS Schluns et al.
NATURE REVIEWS IMMUNOLOGY (2003)
Cytokine-driven proliferation and differentiation of human naive, central memory and effector memory CD4+ T cells
J Geginat et al.
PATHOLOGIE BIOLOGIE (2003)
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15
RJ Brentjens et al.
NATURE MEDICINE (2003)
IL-15Rα recycles and presents IL-15 in trans to neighboring cells
S Dubois et al.
IMMUNITY (2002)
Interleukin 15: biology and relevance to human disease
TA Fehniger et al.
BLOOD (2001)
IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice
J Marks-Konczalik et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
